Rosiglitazone is an anti-diabetic drug from the thiazolidinedione class. It is being marketed as Avandia® by the pharmaceutical company GlaxoSmithKline, both as a standalone preparation and in combination with metformin (Avandamet®). Another combination drug approved by the FDA is Avandaryl® (with glimepiride).
Like other thiazolidinediones, its mechanism of action is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a pure ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone (Mohanty et al).

Avandia - GlaxoSmithKline - Official product site with information primarily intended for diabetics. Includes free membership area.
Meta Description: [ Find information on the diabetes medication Avandia, as well as managing type 2 diabetes. ]
Avandia Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling (as pdf).
DrugDigest: Rosiglitazone ( Avandia ) - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
| Avandia and Diabetic Macular Edema (March 2006) | |
| Next Video | |